AMN
MCID: ADR022
MIFTS: 39

Adrenomyeloneuropathy (AMN)

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adrenomyeloneuropathy

MalaCards integrated aliases for Adrenomyeloneuropathy:

Name: Adrenomyeloneuropathy 20 71
Adrenoleukodystrophy 71
Amn 20

Classifications:



External Ids:

UMLS 71 C0162309 C1527231

Summaries for Adrenomyeloneuropathy

GARD : 20 Adrenomyeloneuropathy (AMN) is an inherited condition that affects the spinal cord. It is a form of X-linked adrenoleukodystrophy. On average, people with AMN begin to develop features in the late twenties. Signs and symptoms may include progressive stiffness and weakness of the legs; ataxia; speech difficulties; adrenal insufficiency; sexual dysfunction; and bladder control issues. Some people with AMN also have brain involvement which can lead to behavioral abnormalities, vision loss, hearing problems, and/or seizures. AMN is caused by changes (mutations) in the ABCD1 gene and is inherited in an X-linked manner. Treatment addresses the symptoms in each person and may include steroid replacement therapy for adrenal insufficiency.

MalaCards based summary : Adrenomyeloneuropathy, also known as adrenoleukodystrophy, is related to adrenoleukodystrophy and peroxisomal disease, and has symptoms including seizures, ataxia and paraparesis. An important gene associated with Adrenomyeloneuropathy is ABCD1 (ATP Binding Cassette Subfamily D Member 1), and among its related pathways/superpathways are G alpha (s) signalling events and Peroxisome. The drugs Prednisolone acetate and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone marrow and liver.

Wikipedia : 74 Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup... more...

Related Diseases for Adrenomyeloneuropathy

Diseases related to Adrenomyeloneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 adrenoleukodystrophy 32.4 SLC25A17 ABCD1
2 peroxisomal disease 29.9 SLC25A17 ABCD1
3 demyelinating disease 29.2 SLC25A17 ABCD1
4 imerslund-grasbeck syndrome 1 11.7
5 megaloblastic anemia 11.4
6 imerslund-grasbeck syndrome 2 11.3
7 vitamin b12 deficiency 11.0
8 3-methylglutaconic aciduria, type i 11.0
9 x-linked cerebral adrenoleukodystrophy 10.9
10 macrocytic anemia 10.9
11 heinz body anemias 10.9
12 donnai-barrow syndrome 10.9
13 vitamin metabolic disorder 10.9
14 congenital intrinsic factor deficiency 10.9
15 3-methylglutaconic aciduria 10.9
16 diphyllobothriasis 10.9
17 tropical sprue 10.9
18 methylmalonic acidemia 10.9
19 spastic paraparesis 10.6
20 peripheral nervous system disease 10.5
21 neuropathy 10.5
22 premature ovarian failure 7 10.3
23 impotence 10.3
24 paraplegia 10.3
25 hypogonadism 10.2
26 spasticity 10.2
27 proteinuria, chronic benign 10.2
28 ataxia and polyneuropathy, adult-onset 10.2
29 primary adrenal insufficiency 10.2
30 autosomal recessive disease 10.1
31 polyneuropathy 10.1
32 hereditary spastic paraplegia 10.1
33 measles 10.1
34 pituitary gland disease 10.0
35 acute adrenal insufficiency 10.0
36 peroxisomal biogenesis disorder 10.0 SLC25A17 ABCD1
37 brucellosis 10.0
38 prostate transitional cell carcinoma 10.0 SLC25A17 AMACR
39 dowling-degos disease 1 10.0
40 hypoadrenocorticism, familial 10.0
41 urinary tract infection 10.0
42 neurogenic bladder 10.0
43 hypothyroidism 10.0
44 thrombocytopenia 10.0
45 testicular disease 10.0
46 inherited metabolic disorder 10.0
47 pathologic nystagmus 10.0
48 rhizomelic chondrodysplasia punctata 10.0 SLC25A17 ABCD1
49 cerebral degeneration 9.9 SLC25A17 ABCD1
50 peroxisome biogenesis disorder 1b 9.9 SLC25A17 ABCD1

Graphical network of the top 20 diseases related to Adrenomyeloneuropathy:



Diseases related to Adrenomyeloneuropathy

Symptoms & Phenotypes for Adrenomyeloneuropathy

UMLS symptoms related to Adrenomyeloneuropathy:


seizures, ataxia, paraparesis, muscle spasticity, absence of sensation, unspecified visual loss

Drugs & Therapeutics for Adrenomyeloneuropathy

Drugs for Adrenomyeloneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
2
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
3
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
4
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
5
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
6
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
7
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10
Biotin Approved, Investigational, Nutraceutical Phase 2, Phase 3 58-85-5 171548
11
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
12 Bile Acids and Salts Phase 3
13 Gastrointestinal Agents Phase 3
14 Cholic Acids Phase 3
15 Vitamin B Complex Phase 2, Phase 3
16 Folate Phase 2, Phase 3
17 Vitamin B9 Phase 2, Phase 3
18 Vitamin B7 Phase 2, Phase 3
19 Antirheumatic Agents Phase 2, Phase 3
20 Methylprednisolone Acetate Phase 2, Phase 3
21 Liver Extracts Phase 3
22 Pharmaceutical Solutions Phase 2, Phase 3
23
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
24
Melphalan Approved Phase 2 148-82-3 4053 460612
25
tannic acid Approved Phase 2 1401-55-4
26
Hydroxyurea Approved Phase 2 127-07-1 3657
27
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
28
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
29
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Mesna Approved, Investigational Phase 2 3375-50-6 598
32
Mycophenolic acid Approved Phase 2 24280-93-1 446541
33
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
34
Tocopherol Approved, Investigational Phase 2 1406-66-2
35
alemtuzumab Approved, Investigational Phase 2 216503-57-0
36
Thiotepa Approved, Investigational Phase 1, Phase 2 52-24-4 5453
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
rituximab Approved Phase 2 174722-31-7 10201696
39
Glycerol Approved, Investigational Phase 2 56-81-5 753
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
41 Tocotrienol Investigational Phase 2 6829-55-6
42 Anti-Infective Agents Phase 2
43 Antiviral Agents Phase 2
44 Anti-Bacterial Agents Phase 2
45 Respiratory System Agents Phase 2
46 Protective Agents Phase 2
47 Antioxidants Phase 2
48 Expectorants Phase 2
49 Antidotes Phase 2
50 Hypoglycemic Agents Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
2 Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
3 Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism Completed NCT00007020 Phase 3 Cholic Acids
4 A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT03852498 Phase 3
5 A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy Active, not recruiting NCT03231878 Phase 2, Phase 3 MIN-102;Placebos
6 A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Active, not recruiting NCT01896102 Phase 2, Phase 3
7 Effect of Plasma Exchange With Albumin in Patients With Adrenomyeloneuropathy: Unicentric, Single Arm, Proof of Concept Study. Not yet recruiting NCT04303416 Phase 2, Phase 3 Albumin solution
8 A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Terminated NCT00545597 Phase 3 Lorenzo's oil
9 A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E Completed NCT01495260 Phase 2 N-acetylcysteine;lipoic acid;vitamin E
10 Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy: a Phase II, Single-arm, Multicentric Clinical Trial Completed NCT03864523 Phase 2 Pioglitazone
11 Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation Completed NCT00383448 Phase 2 Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea
12 Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders Completed NCT01043640 Phase 2 Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
13 A Phase I/II Clinical Trial of Lentiviral Hematopoietic Stem Cell Gene Therapy for Treatment of Developed Metachromatic Leukodystrophy and Adrenoleukodystrophy Recruiting NCT02559830 Phase 1, Phase 2
14 An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Recruiting NCT04528706 Phase 2 MIN-102
15 PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
16 MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG Recruiting NCT02171104 Phase 2 IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
17 Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease Recruiting NCT03367546 Phase 2
18 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
19 Study of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil) Therapy in Male Children With Adrenoleukodystrophy Terminated NCT00004418 Phase 2 glyceryl trierucate/glyceryl trioleate
20 Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD) Withdrawn NCT03196765 Phase 1, Phase 2 Sobetirome (NV1205)
21 Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
22 A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Active, not recruiting NCT02595489 Phase 1
23 A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
24 A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD) Withdrawn NCT01787578 Phase 1 Sobetirome
25 MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD) Withdrawn NCT02410239 Phase 1
26 Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT00005900
27 Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Unknown status NCT00278044
28 Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Completed NCT00004450 glyceryl trierucate;glyceryl trioleate;interferon beta;thalidomide
29 Newborn Screening for Adrenoleukodystrophy Completed NCT02952482
30 A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Gait in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Completed NCT03627416
31 Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD) Completed NCT01165060 Bezafibrate
32 Exercise Study of Function and Pathology for Women With X-ALD Completed NCT01594853
33 Quality of Life in Female Carriers of X-linked Adrenoleukodystrophy Recruiting NCT04675749
34 Adrenoleukodystrophy National Registry Study Recruiting NCT03789721
35 Lentiviral Gene Therapy for X-linked Adrenoleukodystrophy (X-ALD) Recruiting NCT03727555
36 A Non-interventional Study to Prospectively Assess Baseline Status and Disease Progression in Male Children With X-Linked Adrenoleukodystrophy Recruiting NCT03278899
37 Precision Exercise Program in Children With Malignant Hemopathies Undergoing Therapy and/or Hematopoietic Stem Cell Transplantation: The "Sport Therapy" Project Recruiting NCT04090268
38 Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Enrolling by invitation NCT02698579
39 SMART-ALD - A New Lifestyle Intervention to Improve Physical and Mental Well-being and Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Not yet recruiting NCT04687007
40 Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy No longer available NCT02233257 Lorenzo's Oil
41 Study of Bile Acids in Patients With Peroxisomal Disorders Terminated NCT00004442 chenodeoxycholic acid;cholic acid;ursodiol
42 A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy Terminated NCT02204904
43 Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy Withdrawn NCT02948062

Search NIH Clinical Center for Adrenomyeloneuropathy

Genetic Tests for Adrenomyeloneuropathy

Anatomical Context for Adrenomyeloneuropathy

MalaCards organs/tissues related to Adrenomyeloneuropathy:

40
Spinal Cord, Bone Marrow, Liver, Cortex, Adrenal Cortex, Bone, Brain

Publications for Adrenomyeloneuropathy

Articles related to Adrenomyeloneuropathy:

(show top 50) (show all 2172)
# Title Authors PMID Year
1
Clinical evaluation of childhood cerebral adrenoleukodystrophy with balint's symptoms. 61
33309491 2021
2
Bilateral testicular masses and adrenal insufficiency: is congenital adrenal hyperplasia the only possible diagnosis? First two cases of TARTS described in Addison-only X-linked adrenoleukodystrophy and a brief review of literature. 61
32691371 2021
3
Utility of measuring very long-chain fatty-acyl carnitines in dried blood spots for newborn screening of X-linked Adrenoleukodystrophy. 61
33552912 2021
4
X-linked adrenoleukodystrophy caused by a novel mutation presenting with various phenotypes in a Taiwanese family. 61
33359056 2021
5
[A pedigree of X-linked adrenoleukodystrophy with hypocorticism]. 61
33503729 2021
6
Pain Study in X-Linked Adrenoleukodystrophy in Males and Females. 61
33609269 2021
7
Genetic testing of leukodystrophies unraveling extensive heterogeneity in a large cohort and report of five common diseases and 38 novel variants. 61
33547378 2021
8
Corrigendum: Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor. 61
33585488 2021
9
Generation of an urine-derived induced pluripotent stem cell line from a 6-year old X-linked adrenoleukodystrophy (X-ALD) patient. 61
33472124 2021
10
Anti-oxidant MitoQ rescue of AWB chemosensory neuron impairment in a C. elegans model of X-linked Adrenoleukodystrophy. 61
33474532 2021
11
Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy. 61
33407709 2021
12
Optical coherence tomography in adult adrenoleukodystrophy: a cross-sectional and longitudinal study. 61
32632637 2021
13
Multiparametric in vivo analyses of the brain and spine identify structural and metabolic biomarkers in men with adrenomyeloneuropathy. 61
33516063 2021
14
Bone marrow transplantation into Abcd1-deficient mice: Distribution of donor derived-cells and biological characterization of the brain of the recipient mice. 61
33332637 2020
15
Sequential infection of Epstein-Barr virus and cryptococcal encephalitis after umbilical cord blood transplantation in a child with X-linked adrenoleukodystrophy. 61
33368928 2020
16
Bilateral Temporal Pole Involvement in Adult-Onset X-Linked Adrenoleukodystrophy. 61
33346786 2020
17
MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. 61
33373467 2020
18
Evolution of adrenoleukodystrophy model systems. 61
33373044 2020
19
Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. 61
33332650 2020
20
Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275. 61
32997393 2020
21
Primary Adrenal Insufficiency in childhood: data from a large nationwide cohort. 61
33247909 2020
22
The Spectrum of MR Imaging Patterns Suggestive of Pediatric Posterior Reversible Encephalopathy Syndrome in Children With Cerebral X-Linked Adrenoleukodystrophy. 61
32770607 2020
23
Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy. 61
33274015 2020
24
Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. 61
33047897 2020
25
Unusual early-onset and severe adrenomyeloneuropathy in women. 61
32367612 2020
26
A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils. 61
33054628 2020
27
Spectrum of Addison's Disease in Children. 61
33143829 2020
28
Adrenoleukodystrophy siblings with a novel ABCD1 missense variant presenting with phenotypic differences: a case report and literature review. 61
33127985 2020
29
Volume of Gadolinium Enhancement and Successful Repair of the Blood-Brain Barrier in Cerebral Adrenoleukodystrophy. 61
32599216 2020
30
Newborn Screening for X-Linked Adrenoleukodystrophy in Georgia: Experiences from a Pilot Study Screening of 51,081 Newborns. 61
33239602 2020
31
Novel and known morbidities of leukodystrophies identified using a phenome-wide association study. 61
33299668 2020
32
Adrenomyeloneuropathy Presenting with Spastic Gait. 61
31950643 2020
33
Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p. 61
32416190 2020
34
Pediatric Primary Adrenal Insufficiency: A 21-year Single Center Experience. 61
32938577 2020
35
Epilepsy in children with leukodystrophies. 61
32388833 2020
36
Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-Adrenoleukodystrophy. 61
32934269 2020
37
Five men with arresting and relapsing cerebral adrenoleukodystrophy. 61
32995952 2020
38
The Clinical Impact of CLIR Tools toward Rapid Resolution of Post-Newborn Screening Confirmatory Testing for X-Linked Adrenoleukodystrophy in California. 61
33123639 2020
39
Improvement of walking in patients with adrenoleukodystrophy treated with fampridine as a compassionate use. 61
32900530 2020
40
High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. 61
32511826 2020
41
Correction to: Optical coherence tomography shows neuroretinal thinning in myelopathy of adrenoleukodystrophy. 61
32436104 2020
42
The Changing Face of Adrenoleukodystrophy. 61
32364223 2020
43
Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy. 61
32616675 2020
44
Chronic Progressive Spastic Paraparesis: Think of Peroxisomal Disorders - A Case Report of X-Linked Adult Onset Adrenoleukodystrophy With an Update on The Latest Treatment Strategies. 61
32923227 2020
45
Adult-Onset Cerebral Adrenoleukodystrophy Without Adrenal Gland Involvement. 61
32953324 2020
46
The Clinical Impact of CLIR Tools toward Rapid Resolution of Post-Newborn Screening Confirmatory Testing for X-Linked Adrenoleukodystrophy in California. 61
33239588 2020
47
PPARδ and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson's disease. 61
32703610 2020
48
Network-based characterization of disease-disease relationships in terms of drugs and therapeutic targets. 61
32657408 2020
49
A case of female adrenoleukodystrophy carrier with insidious neurogenic bladder. 61
32742905 2020
50
Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy. 61
32077106 2020

Variations for Adrenomyeloneuropathy

Expression for Adrenomyeloneuropathy

Search GEO for disease gene expression data for Adrenomyeloneuropathy.

Pathways for Adrenomyeloneuropathy

Pathways related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.32 CGA ADM
2 11.05 SLC25A17 AMACR ABCD1
3
Show member pathways
10.52 SLC25A17 AMACR ABCD1

GO Terms for Adrenomyeloneuropathy

Cellular components related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxisomal membrane GO:0005778 9.16 SLC25A17 ABCD1
2 integral component of peroxisomal membrane GO:0005779 8.96 SLC25A17 ABCD1
3 peroxisome GO:0005777 8.8 SLC25A17 AMACR ABCD1

Biological processes related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid beta-oxidation GO:0006635 8.96 SLC25A17 ABCD1
2 fatty acid beta-oxidation using acyl-CoA oxidase GO:0033540 8.62 AMACR ABCD1

Molecular functions related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 CGA ADM

Sources for Adrenomyeloneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....